Xiaobo Feng1, Mei Zhu2, Bingling Liao1, Tianning Tian3, Minhong Li1, Zhibo Wang1, Guoyan Chen4. 1. Department of Diagnosis and Treatment of Gastrointestinal Disease, Shanghai No. 7 People's Hospital, Shanghai, China. 2. Department of Administration and General Family Medicine, Jinqiao Community Health Service Center in Pudong New Area, Shanghai, China. 3. Emergency Trauma Center, Shanghai No. 7 People's Hospital, Shanghai, China. 4. Department of Diagnosis and Treatment of Gastrointestinal Disease, Shanghai No. 7 People's Hospital, Shanghai, China, peininy40108@163.com.
Abstract
BACKGROUND: Accumulating evidence indicates that micro-RNAs play a key role in tumor progression and prognosis. However, the overall biological role and clinical significance of microRNA-552 (miR-552) in the pathogenesis of gastric cancer (GC) remain unclear. METHODS: miR-552 expression was measured in 122 pairs of cancerous and noncancerous tissues and cell lines by quantitative real-time polymerase chain reaction. The relationship between miR-552 and the clinical parameters of patients was analyzed by the χ2 test; Kaplan-Meier analysis and multivariate Cox regression analysis were used to predict the overall survival time and prognosis of patients with different expression of miR-552. Finally, CCK-8 and Transwell were used to detect the changes in cell proliferation, migration, and invasion ability. RESULTS: miR-552 was expressed at markedly high levels in GC tissues compared to normal tissues and in some GC cell lines (p < 0.001). The upregulation of miR-552 was significantly associated with tumors with advanced TNM stage (p = 0.026), lymph node metastasis (p = 0.018), intestinal metaplasia (p = 0.044), and genomically stable subtype (p = 0.035). Moreover, GC patients with high miR-552 expression showed shorter overall survival (log-rank test, p = 0.011) than those with low expression. Meanwhile, miR-552 was an independent prognostic factor for GC patients (HR 5.657, 95% CI 1.619-19.761, p = 0.007). Finally, miR-552 overexpression promoted the proliferation, migration, and invasion of GC cells (p < 0.01). CONCLUSION: Taken together, our results indicate that miR-552, as an oncogene of GC, can promote cell proliferation, migration, and invasion, and miR-552 may be a novel prognostic biomarker for GC.
BACKGROUND: Accumulating evidence indicates that micro-RNAs play a key role in tumor progression and prognosis. However, the overall biological role and clinical significance of microRNA-552 (miR-552) in the pathogenesis of gastric cancer (GC) remain unclear. METHODS:miR-552 expression was measured in 122 pairs of cancerous and noncancerous tissues and cell lines by quantitative real-time polymerase chain reaction. The relationship between miR-552 and the clinical parameters of patients was analyzed by the χ2 test; Kaplan-Meier analysis and multivariate Cox regression analysis were used to predict the overall survival time and prognosis of patients with different expression of miR-552. Finally, CCK-8 and Transwell were used to detect the changes in cell proliferation, migration, and invasion ability. RESULTS:miR-552 was expressed at markedly high levels in GC tissues compared to normal tissues and in some GC cell lines (p < 0.001). The upregulation of miR-552 was significantly associated with tumors with advanced TNM stage (p = 0.026), lymph node metastasis (p = 0.018), intestinal metaplasia (p = 0.044), and genomically stable subtype (p = 0.035). Moreover, GCpatients with high miR-552 expression showed shorter overall survival (log-rank test, p = 0.011) than those with low expression. Meanwhile, miR-552 was an independent prognostic factor for GCpatients (HR 5.657, 95% CI 1.619-19.761, p = 0.007). Finally, miR-552 overexpression promoted the proliferation, migration, and invasion of GC cells (p < 0.01). CONCLUSION: Taken together, our results indicate that miR-552, as an oncogene of GC, can promote cell proliferation, migration, and invasion, and miR-552 may be a novel prognostic biomarker for GC.